Literature DB >> 17464269

PET in genitourinary tract cancers.

S Fanti1, C Nanni, V Ambrosini, M D Gross, D Rubello, M Farsad.   

Abstract

Genitourinary (GU) tract cancers comprise a variety of tumors, which includes some of the most common malignancies in men and women. As a result of the importance of GU neoplasms and the success of positron emission tomography (PET) in imaging and staging cancer, PET with fluorodeoxyglucose (FDG) has been used to depict and stage ovarian, cervical and testicular cancers. The early success of FDG PET in imaging GU tumors is tempered by the fact that some neoplasms of GU origin do not accumulate sufficient FDG for successful imaging. As a result, alternative agents, such as [11C]choline and [11C]acetate, have been used to image prostate cancer and may have utility in bladder cancer, while other PET agents are currently under active evaluation for this and other GU neoplasms. In this paper, we review the current literature and our experience in role of PET in imaging cancers of the GU tract.

Entities:  

Mesh:

Year:  2007        PMID: 17464269

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  6 in total

1.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.

Authors:  Chiara Fuccio; Riccardo Schiavina; Paolo Castellucci; Domenico Rubello; Giuseppe Martorana; Monica Celli; Claudio Malizia; Marta Barios Profitos; Maria Cristina Marzola; Vincenzina Pettinato; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 2.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 3.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

4.  Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.

Authors:  S Schwarzenböck; M Souvatzoglou; B J Krause
Journal:  Theranostics       Date:  2012-03-15       Impact factor: 11.556

Review 5.  A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling?

Authors:  Cyril Fersing; Ahlem Bouhlel; Christophe Cantelli; Philippe Garrigue; Vincent Lisowski; Benjamin Guillet
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

Review 6.  Choline Metabolism Alteration: A Focus on Ovarian Cancer.

Authors:  Marina Bagnoli; Anna Granata; Roberta Nicoletti; Balaji Krishnamachary; Zaver M Bhujwalla; Rossella Canese; Franca Podo; Silvana Canevari; Egidio Iorio; Delia Mezzanzanica
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.